AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

{
  "signal_id": "2b8387ff-1370-e694-e565-60bf80ceffc9",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-30T05:00:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/abbvie-showcases-leadership-in-dermatology-research-with-new-clinical-and-real-world-evidence-across-immune-mediated-skin-diseases-at-2026-eadv-congress-302891825.html",
    "title": "AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress",
    "excerpt": "NORTH CHICAGO, Ill. , Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, September 30 – October 3 in Vienna, Austria. The breadth of data from 60 abstracts, including three late-breaking presentations, reflects AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin diseases, and includes the investigational compounds lutikizumab and zumilokibart, and approved therapies, SKYRIZI ® (risankizumab) and RINVOQ ® (upadacitinib). \"At EADV, we are excited to share new data that further strengthen the growing evidence base across our dermatology portfolio, including SKYRIZI, RINVOQ and investigational therapies,\" said Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie. \"These findings underscore our ongoing research in advancing scientific understanding and delivering innovative treatment options that have the potential to meaningfully improve outcomes for patients across a broad spectrum of immune-mediated skin diseases.\" Key data to be presented across the following therapeutic areas include: The 2026 EADV Congress program is available here , including the late-breaking sessions. Select abstracts and oral presentations from AbbVie include: Abstract Title Session Details...",
    "product": "lutikizumab",
    "summary": "AbbVie is developing lutikizumab, an investigational compound for Hidradenitis Suppurativa, with data from a Phase 2 study presented at the 2026 EADV Congress.",
    "location": "NORTH CHICAGO, Ill.",
    "planning": true,
    "confidence": 0.8,
    "product_data": {
      "name": "lutikizumab",
      "full_text": "investigational compound lutikizumab",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-30T05:00:00Z",
    "location_data": [
      {
        "city": "North Chicago",
        "state": "Illinois",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "The breadth of data from 60 abstracts, including three late-breaking presentations, reflects AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin diseases, and includes the investigational compounds lutikizumab and zumilokibart, and approved therapies, SKYRIZI ® (risankizumab) and RINVOQ ® (upadacitinib)."
  }
}

curl https://signals.autobound.ai/v1/signals/2b8387ff-1370-e694-e565-60bf80ceffc9 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'